# Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

> **NCT01910389** · PHASE3 · TERMINATED · sponsor: **Carelon Research** · enrollment: 23 (actual)

## Conditions studied

- Heart Failure
- Pulmonary Hypertension

## Interventions

- **DRUG:** Tadalafil
- **DRUG:** Placebo for tadalafil

## Key facts

- **NCT ID:** NCT01910389
- **Lead sponsor:** Carelon Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** terminated by funding agency
- **Last updated:** 2015-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910389, "Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01910389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*